Jeffrey E Jones

Mr. Jeffrey E Jones

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JJJeffrey E Jones
Jeffrey E Jones
KTKevin S Tang
Kevin S Tang
AEAilin Barseghian El-Farra
Ailin Barseghian El-Farra
Nathan D. WongNathan D. Wong
Nathan D. Wong
Over the last half-century, discussions on the exact targets for low-density lipoprotein cholesterol (LDL-C) reduction have evolved towards a more aggressive approach with lower LDL-C targets, particularly for high-risk patients with pre-existing atherosclerotic cardiovascular disease (ASCVD). A wealth of cardiovascular outcome trials have shown the efficacy of statin therapy in general, as well as the incremental impact of high-intensity statin therapy in particular. More recent trials have further demonstrated the impact of non-statin therapies, including ezetimibe, proprotein convertase subtilisin/kexin type 9 inhibitors, and, most recently, bempedoic acid, on reducing ASCVD outcomes. The availability of these and other newer therapies has prompted clinicians to strive for lower LDL-C targets to address residual ASCVD risk after statin therapy. This paper will provide an overview of the historical trends in lipid management and therapeutics and review the current state of evidence for lower LDL-C targets in clinical guidelines and recommendations.

16 December 2025 in American Journal of Hypertension
Verified
Journal Article
Closed access
SJShreeya R Joshee
Shreeya R Joshee
KDKyra Dingle
Kyra Dingle
JJJeffrey E Jones
Jeffrey E Jones
AMArun Mahtani
Arun Mahtani
DPDhruvil Ashishkumar Patel
Dhruvil Ashishkumar Patel
JHJiun-Ruey Hu
Jiun-Ruey Hu
Introduction: Hypertension, a major contributor to cardiovascular mortality, requires multimodal monitoring and management strategies for optimal blood pressure (BP) control. Patients are turning toward mobile health (mHealth) applications to manage hypertension which vary widely in design and regulation. This study examines the landscape of hypertension mHealth applications on Apple App Store and Google Play Store and qualitatively evaluates their functionality and security features from patient and clinician perspectives. Methods: Publicly available applications were identified using keyword “hypertension” on the Apple App Store and Google Play Store or in a recent meta-analysis that met specific review criteria. Applications with <1000 reviews (Apple App Store) or 700 applications, 43 underwent full application screening and 18 were reviewed for general information, storage, revenue models, security, patient/clinician interfaces, and associated research. Discrepancies were resolved through consensus and available manufacturer confirmation. Results: Clinician interfaces were largely absent, with limited EMR integration and alert systems. Revenue models ranged from free to subscription-based. Security and data privacy policies varied with applications lacking clear opt-out options for data collection. Patient interfaces offered BP tracking and reminders, and accessibility features. Sentiment analysis showed an overall positive view of frequently reviewed Google Play Store applications. Conclusions: Current mHealth applications lack several features for optimal hypertension monitoring and management. Based on the range of qualitative application features assessed, we formulate a framework for developing an ideal mHealth application for optimal hypertension management.

7 August 2024 in Brain & Heart
Verified
Journal Article
Open access
PDF file
KDKyra Dingle
Kyra Dingle
JJJeffrey E Jones
Jeffrey E Jones
DPDhruvil Ashishkumar Patel
Dhruvil Ashishkumar Patel
CTCamila Trejo-Paredes
Camila Trejo-Paredes
LRLynda E. Rosenfeld
Lynda E. Rosenfeld
JHJiun-Ruey Hu
Jiun-Ruey Hu
Atrial fibrillation (AF) is a significant risk factor for cardioembolic stroke; however, therapeutic anticoagulation for stroke prevention in patients with AF also increases the risk of bleeding. Over the past two decades, extensive efforts have focused on refining patient stratification into risk categories to guide the selection of anticoagulant therapy. Various scores have been developed to estimate stroke risk in patients with AF, including CHADS2, Framingham, CHA2DS2-VASc, ATRIA, ABC, GARFIELD-AF, and IMRS-VASc, with CHA2DS2-VASc being the most widely utilized. Similarly, scores such as HEMORR2HAGES, HAS-BLED, ORBIT, ATRIA, GARFIELD-AF, and the newly introduced DOAC are utilized to estimate bleeding risk, with HAS-BLED being predominant. In recent years, numerous digital tools have been developed to assist physicians and patients in visualizing the risk of stroke and bleeding in an interactive manner, to strengthen the use of evidence-based medicine, and to facilitate shared decisionmaking. These tools include the American College of Cardiology’s AnticoagEvaluator app, Mayo Clinic Anticoagulation Choice Decision Aid, Stroke Prevention in Atrial Fibrillation Risk Tool (SPARCtool), GARFIELD-AF Risk Calculator, and CardioSmart Atrial Fibrillation and Bleeding Risk Calculator. This review explores the evolution of these risk scores, evaluating their merits and drawbacks while highlighting common variables across multiple risk scores. In addition, it describes the landscape of novel digital tools designed for decision-making, offering insights from the perspective of physician users.

2 August 2023 in Cardiovascular Drugs and Therapy
Verified
Journal Article
Closed access
PDF file
RPRajiv C. Patel
Rajiv C. Patel
JJJeffrey E Jones
Jeffrey E Jones
GSGeorge A. A Stouffer
George A. A Stouffer